Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Large Cap Core AlphaDEX UCITS ETF 05.11.2026 FEX.LN IE00B8X9NW27 1,372,712.00 USD 153,130,357.63  111.553  ...

BELLEVUE, Wash.--(BUSINESS WIRE)--Terreno Realty Corporation Acquires Property in Hyattsville, MD for $23.1 Million...

TAMPA, Fla.--(BUSINESS WIRE)--XTEND AI Robotics, Inc. (NYSE: XTND) (“XTEND” or the “Company”), a leader in software systems and Physical AI, today announced that its Asia-Pacific subsidiary, Performance Rotors Pte Ltd, has received a purchase order valued at approximately $8.3 million from a defense customer in the region. The order covers multiple unmanned aerial systems, with associated ground control stations and accessories, and includes a first-year software update package for every system...

ATHENS, Greece--(BUSINESS WIRE)--Piraeus Bank S.A. (“Piraeus” or the “Company”) informs the investment community that its shareholder, Paulson & Co. Inc. (“Paulson”), notified the Company on 04 November 2026 of the following statement: <<As part of a portfolio rebalancing today, Paulson & Co. reduced its stake in Piraeus to approximately 104 million shares or 8.4% of the Company. After the sale, Paulson continues to be the largest shareholder of Piraeus. Paulson has been a long-te...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Arrowstreet Capital, Limited Partnership (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that two research abstracts evaluating its AI-powered electrocardiogram (AI-ECG) technology within the Viz Cardio Suite have been accepted for presentation at the Hypertrophic Cardiomyopathy Medical Society (HCMS) meeting, held in conjunction with the American Heart Association’s Scientific Sessions 2026 in Chicago. Both studies focus on Viz HCM, the suite’s AI-E...

TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it has entered into a new accelerated stock repurchase agreement (“ASR”) with Goldman Sachs & Co. LLC (“Goldman Sachs”), to repurchase $270 million of Align’s common s...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Marvell Technology, Inc. (NASDAQ: MRVL), a leader in data infrastructure semiconductor solutions, today announced it will conduct a conference call following the release of its third quarter of fiscal year 2027 financial results on Tuesday, December 1, 2026, at 1:30 p.m. Pacific Time. Conference Call Interested parties may join the live conference call without operator assistance at Call me™ (link will be active approximately 30 minutes before the call) to...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced positive updated results in patients with immune-checkpoint inhibitor (ICI)-resistant advanced melanoma from the Phase 1 single-center first-in-human (FIH) study and the Phase 1/2 Agni-01 multicenter study of amsokigene autoleucel (amsoki-ce...

LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic, imneskibart (AU-007), today announced positive Phase 2 data demonstrating clinical activity with imneskibart-based regimens in heavily pretreated patients with doublet checkpoint inhibitor (CPI)-refractory melanoma and CPI-refractory adenocarcinoma non-small cell lung cancer (NSCLC). The findings, presented i...